Theratechnologies (TSE:TH) had its target price raised by stock analysts at National Bank Financial from C$11.00 to C$14.00 in a research report issued on Wednesday. The firm presently has an “outperform” rating on the stock. National Bank Financial’s price target suggests a potential upside of 1.97% from the company’s current price.
A number of other research firms have also recently weighed in on TH. Canaccord Genuity upped their price target on Theratechnologies from C$9.50 to C$13.00 in a report on Wednesday, March 7th. CIBC increased their target price on Theratechnologies from C$10.30 to C$15.00 in a research note on Wednesday, March 7th.
TSE TH opened at C$13.73 on Wednesday. Theratechnologies has a fifty-two week low of C$4.96 and a fifty-two week high of C$13.50.
In other Theratechnologies news, Director Jean-Denis Talon bought 2,700 shares of Theratechnologies stock in a transaction dated Monday, April 9th. The stock was bought at an average cost of C$9.44 per share, for a total transaction of C$25,488.00. Over the last quarter, insiders have bought 4,100 shares of company stock valued at $37,792.
Theratechnologies Company Profile
Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. The company's lead product is EGRIFTA, which increases the incidence or progression of diabetic retinopathy in diabetic HIV-infected patients with lipodystrophy and excess abdominal fat in the United States and Canada.
Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.